Tonix Pharmaceuticals licenses selective sigma-1 antagonist TNX-4900
Tonix Pharmaceuticals (NASDAQ:TNXP) has secured exclusive worldwide rights to TNX-4900, a selective small-molecule Sigma-1 receptor antagonist positioned as a potential new treatment for chronic neuropathic pain.





















